Biotech Values

[genisi]

GSK’s Nucala (mepolizumab) for asthma

Nucala is approved for patients who have a history of severe asthma attacks (exacerbations) despite receiving their current asthma medicines.

It is the first approved anti IL-5 mAb and will be used indeed in severe patients only, but it gives a new treatment option for these uncontrolled patients.